Enliven Therapeutics, Inc. - 10-Q Filing
Enliven Therapeutics filed its Q1 2026 10-Q report with the SEC, disclosing financial results for the quarter ended March 31, 2026. The company reported a net loss of $25.8 million, or $0.42 per share, compared to a net loss of $19.4 million, or $0.35 per share, in the same period in 2025. Total operating expenses increased to $26.3 million from $19.9 million year-over-year, primarily due to higher research and development costs. As of March 31, 2026, the company had $104.5 million in cash, cash equivalents, and short-term investments.
Tickers: $ELVN